Morin
Based on 10 publication(s) in Google Scholar
Morin is an orally active plant-derived flavonoid. Morin inhibits ROS generation. Morin induces Apoptosis. Morin inhibits PTP1B (IC50 of 15 μM) and activates the insulin receptor. Morin has a detoxifying effect. Morin can be used in diabetes, leukemia, colon cancer, cervical cancer, Parkinson's disease and hypertension research.
For research use only. We do not sell to patients.
- Purity: 97.43%
- CAS No.: 480-16-0
- Formula: C15H10O7
- Molecular Weight:302.24
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Morin
More- Nat Commun. 2023 Jun 10;14(1):3445. [Abstract]
- J Pharm Anal. 2023 May;13(5):514-522. [Abstract]
- Phytomedicine. 2023 Jul 25:116:154866. [Abstract]
- Free Radic Biol Med. 2026 Aug 1:251:276-292. [Abstract]
- Plant Physiol. 2023 Aug 31;193(1):821-839. [Abstract]
- Plant J. 2024 Jul;119(1):197-217. [Abstract]
- Plant Cell Rep. 2024 Dec 4;43(12):301. [Abstract]
- ACS Omega. 2025 Feb 20;10(8):7920-7936. [Abstract]
- J Integr Med. 2025 Apr 22:S2095-4964(25)00050-0. [Abstract]
- J Mol Histol. 2026 Feb 4;57(1):69. [Abstract]
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Gel Electrophoresis
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| H9 | EC50 |
>331 μM
Compound: 15
|
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
|
[PMID: 8158164] |
| H9 | IC50 |
>331 μM
Compound: 15
|
Cytotoxicity against human H9 cells after 3 days
Cytotoxicity against human H9 cells after 3 days
|
[PMID: 8158164] |
| HEK293 | IC50 |
12.3 μM
Compound: Morin
|
Inhibition of human recombinant BACE-1 expressed in HEK293 cells assessed as inhibition of amyloid precursor protein cleavage into amyloid beta after 60 mins using Rh-EVNLDAEFK-Quencher as a substrate by FRET assay
Inhibition of human recombinant BACE-1 expressed in HEK293 cells assessed as inhibition of amyloid precursor protein cleavage into amyloid beta after 60 mins using Rh-EVNLDAEFK-Quencher as a substrate by FRET assay
|
[PMID: 21511472] |
| HEK293 | IC50 |
2 μM
Compound: morin
|
Inhibition of human URAT1-mediated urate uptake in HEK293 cells
Inhibition of human URAT1-mediated urate uptake in HEK293 cells
|
[PMID: 17325024] |
| HT-29 | EC50 |
1.33 μM
Compound: Morin
|
Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay
Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay
|
[PMID: 24900447] |
| HT-29 | IC50 |
1.6 μM
Compound: Morin
|
Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins
Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins
|
[PMID: 24900447] |
| Huh-7 | CC50 |
>50 μM
Compound: 38
|
Cytotoxicity against human Huh7.5.1 cells by MTT assay
Cytotoxicity against human Huh7.5.1 cells by MTT assay
|
[PMID: 22445328] |
| L929 | EC50 |
115 μM
Compound: morin
|
Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay
Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay
|
[PMID: 9287415] |
| L929 | EC50 |
120 μM
Compound: morin
|
Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining
Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining
|
[PMID: 9287415] |
| MCF7 | IC50 |
49 μM
Compound: 14
|
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
|
[PMID: 21354800] |
| MDCK | IC50 |
21 μM
Compound: 14
|
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
|
[PMID: 21354800] |
| U2OS | EC50 |
11.2 μM
Compound: Morin
|
Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay
Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay
|
[PMID: 24900447] |
Morin (25 μM, 1 h) protects V79-4 cells from hydrogen peroxide-induced damage by inhibiting ROS generation and by inducing catalase activation[3].
Morin (100-500 μM, 6-48 h) inhibits the growth of human leukemia HL-60 cells via cell cycle arrest and induction of apoptosis through mitochondria dependent pathway[4].
Morin (50 μM, 0-70 h) inhibits growth and activates the insulin metabolic pathway in HepG2 cells[5].
Morin (100-500 μM, 48 h) shows anti-cancerous activity against HeLa cells at an IC50 of 214.28 μM and causes morphological changes[6].
Morin (5-50 μM, 24 h) exerts neuroprotective actions in PC12 cells, with attenuating loss of cell viability[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HL-60
-
Concentration:100, 200, 300, 400, 500 μM
-
Incubation Time:6 h, 12 h, 24 h, 48 h
-
Result:Decreased the percentage of viable cells at a dose- and time-dependent manner.
-
Cell Line:HL-60
-
Concentration:100, 200, 300, 400, 500 μM
-
Incubation Time:6 h, 12 h, 24 h, 48 h
-
Result:Induced apoptosis in a dose-dependent manner.
Promoted the activation of caspase-3.
-
Cell Line:HL-60
-
Concentration:100, 200, 300, 400, 500 μM
-
Incubation Time:6 h, 12 h, 24 h, 48 h
-
Result:Induced G2/M arrest.
Morin (10-150 mg/kg, i.p., 30 min prior to γ-irradiation) shows anticlastogenic activity against whole body gamma irradiation in Swiss albino mice[8].
Morin (100 mg/kg, intragastrically, 10 days) exacerbates Cyclophosphamide (HY-17420)-induced suppression of body weight gain in rats[9].
Morin (Morin hydrate form, 100 mg/kg, p.o., 10 days) attenuates Doxorubicin (HY-15142A)-induced heart and brain damage by reducing oxidative stress, inflammation and apoptosis in rats[10].
Morin (50 mg/kg, p.o., everyday for a total period of 30 weeks) could exert a significant chemopreventive effect on colon carcinogenesis induced by DMH in rats[11].
Morin (25-75 mg/kg, p.o., 6 weeks) exhibits strong antihypertensive effect against DOCA-salt induced hypertension in rats[12].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 480-16-0
-
Appearance Solid
-
Molecular Weight 302.24
-
Formula C15H10O7
-
Color Light yellow to yellow
-
SMILES
O=C1C(O)=C(C2=CC=C(O)C=C2O)OC3=CC(O)=CC(O)=C13
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2023 Jun 10;14(1):3445. PMID: 37301862 -
J Pharm Anal
A robust luminescent assay for screening alkyladenine DNA glycosylase inhibitors to overcome DNA repair and temozolomide drug resistance. [Abstract]2023 May;13(5):514-522. PMID: 37305785
Morin purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2023 May;13(5):514-522. [Abstract]
A dose-response experiment further confirmed the AAG inhibitory activity of sunitinib, which showed even greater inhibition of AAG activity (81.2% at 10 μM) compared to the positive control Morin.
Morin purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2023 May;13(5):514-522. [Abstract]
Steady-state emission spectra of the probe with AAG (100 U/mL), AAG (100 U/mL) + 10 μM Morin, or AAG (100 U/mL) + 10 μM sunitinib. With excitation at 355 nm, the intensity of the luminescence emission was measured between 450 and 700 nm.
Morin purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2023 May;13(5):514-522. [Abstract]
DNA assay reaction products were subjected to polyacrylamide gel electrophoresis analysis and silver staining regardless of the presence of Sunitinib or Morin.
-
Phytomedicine
Morin exhibits a neuroprotective effect in MPTP-induced Parkinson's disease model via TFEB/AMPK-mediated mitophagy. [Abstract]2023 Jul 25:116:154866. PMID: 37209604
Morin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Jul 25:116:154866. [Abstract]
Morin (6.25, 12.5, 25, 50 μM; 24 h) decreases the expression of p-TFEB (ser142) and cytoplasm TFEB (Flag-TFEB) dose-dependently in Hela cells.
Morin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Jul 25:116:154866. [Abstract]
Morin (25 μM; 24 h) significantly promotes TFEB nuclear translocation in CF7 cells.
-
Free Radic Biol Med
Bisphenol A drives thyroid carcinogenesis through oxidative stress-lipid metabolic reprogramming via the PTEN/PI3K/AKT axis: Therapeutic reversal by a curcumin-modified quercetin nanomicelle system. [Abstract]2026 Aug 1:251:276-292. PMID: 41985638 -
Plant Physiol
Melatonin promotes Al3+ compartmentalization via H+ transport and ion gradients in Malus hupehensis. [Abstract]2023 Aug 31;193(1):821-839. PMID: 37311207 -
Plant J
Strigolactones alleviate AlCl3 stress by vacuolar compartmentalization and cell wall blocking in apple. [Abstract]2024 Jul;119(1):197-217. PMID: 38565306 -
Plant Cell Rep
2024 Dec 4;43(12):301. PMID: 39630276 -
ACS Omega
Unveiling Natural Power: Morin and Myricetin as Potent Inhibitors of Histidinol-Phosphate Aminotransferase in Drug-Resistant Acinetobacter baumannii. [Abstract]2025 Feb 20;10(8):7920-7936. PMID: 40060852
Morin purchased from MedChemExpress. Usage Cited in: ACS Omega. 2025 Feb 20;10(8):7920-7936. [Abstract]
Intrinsic fluorescence quenching of AbHPA by different concentrations of Morin ranging from 0 to 48 μM (0, 6, 12, 24 and 48 μM) in the Tris-HCl buffer and pH 8.0 at 25 ℃.
Morin purchased from MedChemExpress. Usage Cited in: ACS Omega. 2025 Feb 20;10(8):7920-7936. [Abstract]
SPR sensograms showing the direct binding of morin and myricetin to AbHPA immobilized on the CM5 chip.
-
J Integr Med
Morin inhibits ubiquitination degradation of BCL-2 associated agonist of cell death and synergizes with BCL-2 inhibitor in gastric cancer cells. [Abstract]2025 Apr 22:S2095-4964(25)00050-0. PMID: 40319008 -
J Mol Histol
2026 Feb 4;57(1):69. PMID: 41636890
Solvent & Solubility
DMSO : 250 mg/mL (827.16 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.88 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.88 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (459 KB)
- English - EN (459 KB)
- Français - FR (459 KB)
- Deutsch - DE (459 KB)
- Norwegian - NO (459 KB)
- Español - ES (459 KB)
- Swedish - SV (459 KB)
- Italian - IT (459 KB)
- Korean - KR (459 KB)
- Portuguese - PT (459 KB)
-
Handling Instructions (2659 KB)
References
[1]. Duthie G, et al. Antioxidant capacity of flavonoids in hepatic microsomes is not reflected by antioxidant effects in vivo. Oxid Med Cell Longev. 2012;2012:165127. [Content Brief]
[2]. Lian HZ, et al. Morin applied in speciation of aluminium in natural waters and biological samples by reversed-phase high-performance liquid chromatography with fluorescence detection. Anal Bioanal Chem. 2003 Jun;376(4):542-8. Epub 2003 May 9. [Content Brief]
[3]. Zhang R, et al. Cellular protection of morin against the oxidative stress induced by hydrogen peroxide. Chem Biol Interact. 2009 Jan 15;177(1):21-7. [Content Brief]
[4]. Kuo HM, et al. Morin inhibits the growth of human leukemia HL-60 cells via cell cycle arrest and induction of apoptosis through mitochondria dependent pathway. Anticancer Res. 2007 Jan-Feb;27(1A):395-405. [Content Brief]
[5]. Paoli P, et al. The insulin-mimetic effect of Morin: a promising molecule in diabetes treatment. Biochim Biophys Acta. 2013 Apr;1830(4):3102-11. [Content Brief]
[6]. Zhang Q, et al. Molecular mechanism of anti-cancerous potential of Morin extracted from mulberry in Hela cells. Food Chem Toxicol. 2018 Feb;112:466-475. [Content Brief]
[7]. Zhang ZT, et al. Morin exerts neuroprotective actions in Parkinson disease models in vitro and in vivo. Acta Pharmacol Sin. 2010 Aug;31(8):900-6. [Content Brief]
[8]. Parihar VK, et al. Anticlastogenic activity of morin against whole body gamma irradiation in Swiss albino mice. Eur J Pharmacol. 2007 Feb 14;557(1):58-65. [Content Brief]
[10]. Kuzu M, et al. Morin attenuates doxorubicin-induced heart and brain damage by reducing oxidative stress, inflammation and apoptosis. Biomed Pharmacother. 2018 Oct;106:443-453. [Content Brief]
[11]. Sreedharan V, et al. Effect of morin on tissue lipid peroxidation and antioxidant status in 1, 2-dimethylhydrazine induced experimental colon carcinogenesis. Invest New Drugs. 2009 Feb;27(1):21-30. [Content Brief]
[12]. Prahalathan P, et al. Effect of morin, a flavonoid against DOCA-salt hypertensive rats: a dose dependent study. Asian Pac J Trop Biomed. 2012 Jun;2(6):443-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3086 mL | 16.5431 mL | 33.0863 mL | 82.7157 mL |
| 5 mM | 0.6617 mL | 3.3086 mL | 6.6173 mL | 16.5431 mL | |
| 10 mM | 0.3309 mL | 1.6543 mL | 3.3086 mL | 8.2716 mL | |
| 15 mM | 0.2206 mL | 1.1029 mL | 2.2058 mL | 5.5144 mL | |
| 20 mM | 0.1654 mL | 0.8272 mL | 1.6543 mL | 4.1358 mL | |
| 25 mM | 0.1323 mL | 0.6617 mL | 1.3235 mL | 3.3086 mL | |
| 30 mM | 0.1103 mL | 0.5514 mL | 1.1029 mL | 2.7572 mL | |
| 40 mM | 0.0827 mL | 0.4136 mL | 0.8272 mL | 2.0679 mL | |
| 50 mM | 0.0662 mL | 0.3309 mL | 0.6617 mL | 1.6543 mL | |
| 60 mM | 0.0551 mL | 0.2757 mL | 0.5514 mL | 1.3786 mL | |
| 80 mM | 0.0414 mL | 0.2068 mL | 0.4136 mL | 1.0339 mL | |
| 100 mM | 0.0331 mL | 0.1654 mL | 0.3309 mL | 0.8272 mL |